MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- GSK PHARMA
GSK PHARMA Share Price (GLXO)
Here is the latest stock price and chart of GSK Pharma. For more details, see the GSK Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Dec 12, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)1,645.75 | Open (Rs) 1,639.75 | High (Rs) 1,650.00 | Low (Rs) 1,630.00 |
| % Change0.84 | Volume 59,391 | Value (Rs) 97,628,810 | 52-Week H/L 1,735.00 / 1,131.05 |
| Live NSE Quotes | Dec 12, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)1,645.35 | Open (Rs) 1,633.00 | High (Rs) 1,654.00 | Low (Rs) 1,627.00 |
| % Change0.81 | Volume 44,366 | Value (Rs) 72,915,829 | 52-Week H/L 1,737.00 / 1,130.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 50.31 | P/E Ratio (x) 32.71 | Market Cap (Rs m) 278,799.92 | P/BV (x) 13.03 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
Listen In: Our Investor Hour Podcast Connects You with the World's Most Successful Investors
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
GSK PHARMA Share Price Today:
GSK PHARMA last traded price was up 0.8% to Rs 1,645.8 on the BSE. On the NSE, GSK PHARMA last traded price was up 0.8% to Rs 1,645.4. The total volume of shares traded was 0.1 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.7%. And the benchmark S&P BSE SENSEX was at 40,581.7 (up 0.4%).
Over the last 30 days, the GSK PHARMA share price is up 2.6%. And over the last one year, GSK PHARMA share price is up 18.7%.
|
| |
Today's Market
Sensex Ends 169 Points Higher; Auto and Metal Stocks Witness Buying(Closing)
Indian share markets continued to trade on a positive note during closing hours and ended their session in the green.
Related Views On News
GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)
Oct 25, 2019 | Updated on Oct 25, 2019For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)
Jul 24, 2019 | Updated on Jul 24, 2019For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Use My Secret to Increase Your Trading Profits Today
Dec 10, 2019What to do after every trade.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020 (Profit Hunter)
Dec 5, 2019This corner of the market could provide more returns than blue chips in 2020.
Make the Most of the Smallcap Rebound with These Stocks (Profit Hunter)
Dec 3, 2019Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
What Is the IPO Euphoria Signaling Us About the Markets? (The 5 Minute Wrapup)
Dec 2, 20192019 will be remembered as the year of great money-making IPOs...
MoreTRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA 5-YR ANALYSIS
COMPARE GSK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.